Revised Chinese regulations that brought a lot of changes in clinical trials and product registrations were received with lots of questions. If you have got questions that are yet unanswered, you are not alone. Many researchers, developers and managers are not sure about one aspect or another on how to comprehend, act or change their […]

Read More →

Outsourcing in clinical trial industry has been on the rise for last several decades. This has been due to a combination of several factors, including increasing cost of research, blockbuster molecules going off-patent causing revenue loss and lack of extensive in-house R&D infrastructure. This has resulted in an interesting situation, where increasingly more clinical trials […]

Read More →

Recently, Thailand FDA has brought a revised list of institutional review boards (IRBs) / ethics committees (ECs) that it recognizes for acceptance of applications. In our previous articles (see Part I and Part II), we’ve discussed about the regulatory scenario in Thailand, including regulatory approvals for clinical trial in Thailand, ethics committee approval for clinical trial in Thailand, […]

Read More →

Investigators, from Brazil who were specialized in Allergy and Immunology segment, were invited to participate in feasibility of a new phase II clinical trial.   What’s was the trial about? It’s a phase II – dose selection and confirmatory – clinical trial planned to be conducted in Brazil. What kind of patients were required for this clinical […]

Read More →